Potential of endogenous regenerative technology for in situ regenerative medicine

被引：144

作者：

Anitua, Eduardo ^{[1
]}

Sanchez, Mikel ^{[2
]}

Orive, Gorka ^{[1
]}

机构：

[1] BTI, Vitoria, Spain

[2] Unidad Cirugia Artroscop Mikel Sanchez, Vitoria 01005, Spain

来源：

ADVANCED DRUG DELIVERY REVIEWS | 2010年 / 62卷 / 7-8期

关键词：

Growth factors; Endogenous regenerative medicine; Platelets; Fibrin; Scaffolds; Biomaterials; PLATELET-RICH PLASMA; TISSUE-ENGINEERED BONE; AUTOLOGOUS PREPARATION RICH; GROWTH-FACTOR REGULATION; MESENCHYMAL STEM-CELLS; DENTAL IMPLANTS; DRUG-DELIVERY; STROMAL CELLS; CONTROLLED-RELEASE; ENDOTHELIAL-CELLS;

D O I：

10.1016/j.addr.2010.01.001

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Endogenous regenerative technology (Endoret) involves the use of patient's own biologically active proteins. growth factors and biomaterial scaffolds for therapeutic purposes. This technology provides a new approach for the stimulation and acceleration of tissue healing and bone regeneration. The versatility and biocompatibility of using patient-derived fibrin scaffold as an autologous, biocompatible and biodegradable drug delivery system open the door to a personalized medicine that is currently being used in numerous medical and scientific fields including dentistry, oral implantology, orthopaedics, ulcer treatment, sports medicine and tissue engineering among others. This review discusses the state of the art and new directions in the use of endogenous technology in the repair and regeneration of injured tissues by means of a controlled and local protein and growth factor delivery. The next generations of engineering strategies together with some of the most interesting therapeutic applications are discussed together with the future challenges in the field. (C) 2010 Elsevier B.V. All rights reserved.

引用

页码：741 / 752

页数：12

共 152 条

[41] PLATELET-DERIVED GROWTH FACTOR-MODULATED GUIDED TISSUE REGENERATIVE THERAPY [J].